Category: CerSci Therapeutics

  • Top 20 Biopharma M&A of 2020 by Total Deal Value

    Biopharma merger and acquisition activity in 2020 was mainly filled with late-stage, bolt-on acquisitions, which were orders of magnitude smaller than the mega M&A deals of prior years. AstraZeneca holds the top rank by acquiring Alexion Pharmaceuticals among the top 20 acquisitions with a total deal value of $39B at a 1-day premium of 45% […]

  • ACADIA Acquires CerSci Therapeutics for $52.5M

    Shots: ACADIA acquires all outstanding shares of CerSci for $52.5M. CerSci may receive up to $887M as development, commercialization milestones along with royalties on sales The acquisition will boost ACADIA’s clinical pipeline with the addition of non-opioid pain therapies including CerSci’s lead candidate ACP-044 ACP-044 has demonstrated a promising effect in the P-I study with an […]